Investor Relations

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

Stock Info
NASDAQVIRX
Recent News
Jun 1, 2021

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the initiation of NAVAL-1 (Nanatinostat in Combination with...

May 27, 2021

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the Jefferies...

May 18, 2021

Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta), a precision oncology company targeting virus-associated malignancies, will host a key opinion leader (KOL) webinar on nanatinostat and...

View All

Events

Download the Needham Presentation

Thursday, June 3, 2021
2:30pm EDT
Thursday, May 20, 2021
2:00pm EDT

The design of NAVAL-1, a global pivotal trial in EBV-positive R/R lymphoma, will be discussed during a Key Opinion Leader webinar on May 20, 2021 at 2pm EST. The webinar will feature presentations by

View All

Investor Contact

Dan Chevallard
Chief Financial Officer
Viracta Therapeutics, Inc.
(o) (858) 771-4193